RxDoctor Payments Data

Amanda Stover, DO

Family Medicine · Canal Winchester, OHNPI 1730473257

Payments from drug & device makers

$4,825in general payments, 2019–2025

Across 293 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$518
  • Pfizer$453
  • Novo Nordisk$378
  • Lilly USA, LLC$318
  • Amgen$288
  • Amarin Pharma, Inc.$274
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$4,813100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,825 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$59,426
Medicare patients
131
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$91,597
OzempicSemaglutide50$80,756
EliquisApixaban69$67,304
XareltoRivaroxaban14$22,680
JanuviaSitagliptin Phosphate16$22,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,190
OxycontinOxycodone Hcl11$15,657
EntrestoSacubitril/Valsartan12$9,466
VascepaIcosapent Ethyl12$8,486
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$7,369
Humalog Kwikpen U-100Insulin Lispro14$7,351
Duloxetine Hcl128$6,073
Breo ElliptaFluticasone/Vilanterol15$5,963
Atorvastatin Calcium399$4,926
Gabapentin135$3,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$137$91,59774 claims
Novo NordiskOzempic$378$80,75650 claims
PfizerEliquis$453$67,30469 claims
GSKTrelegy Ellipta, Breo Ellipta$160$27,15339 claims
Johnson & JohnsonXarelto$27$22,68014 claims
MerckJanuvia$248$22,50516 claims
NovartisEntresto$186$9,46612 claims
AbbVieSynthroid$518$88515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Canal Winchester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →